From liver to gut: the hidden gastrointestinal impact of pediatric metabolic dysfunction-associated steatotic liver disease
MASLD is a significant early-life risk factor for various GI comorbidities, highlighting the need for thorough GI assessment in pediatric MASLD management. Early detection, prevention, and comprehensive management are essential to reduce long-term complications and slow disease progression. Developing pediatric-specific guidelines and validated noninvasive biomarkers is crucial to enable standardized screening, risk stratification, and monitoring. Continued research - especially incorporating omics technologies - is vital for improving risk prediction, enabling earlier diagnosis, and advancing personalized therapies, ultimately enhancing outcomes and reducing disease burden.
Authors
- Rogério Tadeu Palma (ORCID: https://orcid.org/0000-0002-0600-8965)
- Anna Di Sessa
- M. De Cesare (ORCID: https://orcid.org/0000-0001-5330-6941)
- Mario Bartiromo
- Emanuele Miraglia del Giudice (ORCID: https://orcid.org/0000-0002-1492-076X)
- Pierluigi Marzuillo (ORCID: https://orcid.org/0000-0003-4682-0170)
- Gabriele Forcina (ORCID: https://orcid.org/0009-0007-0385-2734)
- F. Casamassima (ORCID: https://orcid.org/0009-0000-6652-2707)
- Vittoria Frattolillo (ORCID: https://orcid.org/0009-0007-2288-343X)
- Assunta Floriano
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- Azienda Ospedaliera Universitaria Università degli Studi della Campania Luigi Vanvitelli (IT)
Publication Details
- Journal
- Expert Review of Gastroenterology & Hepatology
- Published
- 2025-12-02
- DOI
- https://doi.org/10.1080/17474124.2025.2600386
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00